reports
Kingsway Financial Services Inc: 1 director
A director at Kingsway Financial Services Inc sold 590,000 shares at 8.430USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live audio webcast will be available to investors and other interested ...
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Robert Driscoll
- Sam Ravina
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
Synaptics Democratizes Edge AI at CES 2025 with Astra AI-Native Platf...
Synaptics Democratizes Edge AI at CES 2025 with Astra AI-Native Platform Showcases purpose-built hardware, open-source development framework, and intelligent connectivity to enable rapid development of context-aware IoT devices SAN JOSE, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ), a provider of AI-enhanced IoT solutions, will showcase its AI-Native processing and intelligent connectivity offerings at CES 2025. While AI is infused throughout its entire sense, process, and connect portfolio for the IoT, the company will specifically demonstrate how its p...
Lesaka to Host Webcast and Conference Call to Review Second Quarter 20...
Lesaka to Host Webcast and Conference Call to Review Second Quarter 2025 Results JOHANNESBURG, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (“Lesaka” or the “Company”) (NasdaqGS:LSAK; JSE: LSK) today announced it will release second quarter 2025 results after the U.S. market close on February 5, 2025. Lesaka management will host a presentation webcast and conference call on February 6, 2025, at 8:00 a.m. Eastern Time (“EST”), which is 3:00 p.m. South Africa Standard Time (“SAST”), to review these results. Presentation webcast via Zoom:Link to access the results webcast: ...
- Jonathan Chaplin
Quick hit: spectrum auction in 2025; implications for Dish and carrier...
Blair published a note this morning that anticipates the FCC receiving authority to auction the AWS-3 licenses that Dish relinquished as part of the NDAA. We think an auction could take place in 2H25. In this brief note, we cover the implications for Dish and for the other carriers.
- Blair Levin
Finally, Hope for a (Small) Spectrum Auction
One of the must-pass pieces of legislation left for this Congress is the National Defense Authorization Act (NDAA). The current draft now includes a provision that would appropriate $3 billion for the Rip and Replace program designed to help small telecom companies remove and replace equipment purchased from Chinese telecommunications equipment companies, equipment Congress believes creates national security risks. The legislation funds the appropriation by allowing the FCC to conduct a one-ti...
Synaptics Extends Veros™ IoT Connectivity Leadership with Dual-Core Bl...
Synaptics Extends Veros™ IoT Connectivity Leadership with Dual-Core Bluetooth® 5.4 and IEEE 802.15.4 System on Chip The SYN20708 supports Bluetooth Classic, BLE, Zigbee, and Thread concurrently to deliver simultaneous connectivity to multiple endpoints in heterogeneous network environments SAN JOSE, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today extended its industry-leading TM IoT connectivity family with the dual-core system on chip (SoC) for Bluetooth® 5.4 and IEEE 802.15.4. The Matter-compliant SoC supports Bluetooth (BT) Classic, Bluetooth Low E...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE)...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EBAY EBAY INC.
BPMC BLUEPRINT MEDICINES CORP.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
YMAB Y-MABS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
BEAM INC.
COGT BEAM THERAPEUTICS
IMNM COGENT BIOSCIENCES INC
VOR IMMUNOME
STX VOR BIOPHARMA
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
ARTV GEMINI THERAPEUTICS INC
PRME ARTIVA BIOTHERAPEUTICS INC
PRIME MEDICINE INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TOL TOLL BROTHERS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GPRO GOPRO INC. CLASS A
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CRM SALESFORCE.COM INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BBY BEST BUY CO. INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
HEAR TURTLE BEACH CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
CRSR CORSAIR GAMING
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
Fate Therapeutics Announces Leadership Transition
Fate Therapeutics Announces Leadership Transition Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Sco...
Fate Therapeutics to Present at Upcoming December Investor Conferences
Fate Therapeutics to Present at Upcoming December Investor Conferences SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 2024 Global Healthcare Conference, including a panel discussion at 2:30 PM ET on Tuesday, December 3, 2024 in Miami, Flo...
Synaptics to Participate at Upcoming Investor Conferences on Tuesday, ...
Synaptics to Participate at Upcoming Investor Conferences on Tuesday, December 3, 2024 and Wednesday, December 4, 2024 SAN JOSE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced its participation in upcoming investor conferences. Ken Rizvi, SVP and Chief Financial Officer, will participate in the UBS Global Technology and AI Conference on Tuesday, December 3, 2024.Ken Rizvi, SVP and Chief Financial Officer, will participate in the Wells Fargo 8th Annual TMT Summit on Wednesday, December 4, 2024. About Synaptics Incorporated: Synaptics (Nasdaq:...
- Jonathan Chaplin
- Jonathan Chaplin
3Q24 Broadband Trends: FWA capacity limits; FWA demand limits
In this iteration of “Broadband Trends” we update our FWA capacity forecast. We also touch on early signs that demand for FWA may be limited, which could prevent mobile operators from reaching capacity limits (or force them to work harder to get there). This could have a big impact on the pace of Cable subscriber growth. Finally, we reprise our work on the competitive positioning of the various operators based on relative NPS scores.
- Jonathan Chaplin
SATS: a thought on the debt exchange
In this note we show how there is at least $0.7BN of additional value on the table that could help narrow the discount DBS bondholders are being asked to accept in order to get the DTV deal across the goal line. We also run through the differences between the four segments EchoStar reports at earnings and the four filing entities they disclose to the SEC. We also update our estimates for DBS, Dish Networks and Hughes now that their 10-Q’s have been filed.
Lesaka to acquire prepaid electricity submetering and payments busines...
Lesaka to acquire prepaid electricity submetering and payments business Recharger, expanding alternative payments offering JOHANNESBURG, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) (“Lesaka” or the “Company”) today announced that it has signed a definitive agreement to acquire 100% of the issued and outstanding ordinary shares of Recharger (Pty) Ltd (“Recharger”), a South African prepaid electricity submetering and payments business. The purchase consideration of ZAR 507 million ($28 million translated at the average exchange rate of $1: ZAR 18.06...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.